Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04262336 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment
A Phase 1 study of Ototoxicity, sponsored by Decibel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 8
- Study locations
NCT04262336 is a Phase 1 study of Ototoxicity that has completed, run by Decibel Therapeutics. The registered enrollment target is 22 participants, below the 153-participant average among 3 other Ototoxicity trials with a reported enrollment target (86% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT04262336, a Phase 1 study of Ototoxicity, has completed, sponsored by Decibel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate whether DB-020 administered via an injection in the middle ear prevents hearing loss in participants who will receive high doses of cisplatin as part of their treatment for cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DB-020
Study Locations (8)
Victoria
- Peter MacCallum Cancer Centre - Melbourne
- Oncology and Palliative Care Research - Melbourne
Florida
- University of Miami Health System - Miami
Kansas
- University of Kansas Medical Center - Kansas City
New York
- Northwell Health Cancer Center - Lake Success
West Virginia
- WVU Cancer Institute - Morgantown
Queensland
- Queensland Head and Neck Cancer Centre - Woolloongabba
Western Australia
- Fiona Stanley Hospital, Clinical Trials Unit Cancer Center - Murdoch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-02-21 |
| Est. Completion | 2023-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04262336
The ClinicalTrials.gov registry entry for NCT04262336 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 153-participant average among 3 other Ototoxicity trials with a reported enrollment target (86% lower). The listed sponsor is Decibel Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ototoxicity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04262336 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Victoria, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT04262336 about?
NCT04262336 is a clinical study titled "Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment". The purpose of this study is to evaluate whether DB-020 administered via an injection in the middle ear prevents hearing loss in participants who will receive high doses of cisplatin as part of their treatment for cancer.
What is the current status of trial NCT04262336?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-02-21. Estimated completion is 2023-05-23.
What conditions does trial NCT04262336 study?
This clinical trial studies the following conditions: Ototoxicity.
What interventions are being tested in trial NCT04262336?
The interventions under investigation include: Placebo (DRUG), DB-020 (DRUG).
Who is sponsoring clinical trial NCT04262336?
This trial is sponsored by Decibel Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04262336 being conducted?
This trial has 8 study locations across Florida, Kansas, New York, West Virginia, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ototoxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.